Share Capital Increase 30/08/2007

Lavipharm S.A., following today’s meeting of the Athens Exchange (ATHEX) which approved the import of 39.293.100 pre-emption rights on the Company’s shares, is in the process of Increasing its Share Capital by approximately euro 37.7 million.

The ex-rights date for the existing shareholders’ is Monday, September 3rd 2007, the trading period is fixed from Friday, September 7th 2007 to Monday September 17th 2007, while the period to exercise the pre-emption right begins on Friday, September 7th 2007 and expires on Friday, September 21st 2007. It is reminded that the new shares will be disposed via pre-emption rights in favour of existing shareholders at the rate of 3 new shares to 10 existing shares, at the distribution price of euro 3.20 each. The existing shareholders can oversubscribe for up to three times their pre-emption rights.

Lavipharm’s major shareholder, Chairman & CEO Dr. Athanase Lavidas, owning 50,59% of the Company’s share capital, will fully exercise his pre-emption rights. EFG TELESIS FINANCE will act as the Offer Advisor, whereas EFG EUROBANK ERGASIAS will act as an underwriter for the free float.

The Greek Offer Memorandum is at the disposal of the investors’ community in electronic form on the websites of the ATHEX (www.ase.gr/content/gr/Companies/ListedCo/Prospectus/), the Capital Market Commission (www.cmc.gov.gr), the Issue’s Advisor of EFG Telesis Finance (www.efgtelesis.gr) and Lavipharm’s (http://www.lavipharm.gr/greek/invrelations/index.asp?section=balance) and will be also available, upon request and free of charge, in printed form both at the offices of the Company and the Issue’s Advisor.